MondayNightIBD

April 25, 2022 - April 17, 2023

This activity is jointly provided by Global Education Group and Bonum CE in partnership with MondayNightIBD.

Program Overview

The past decade in the management of inflammatory bowel disease (IBD) has been a substantial shift leading to improved care and patient outcomes. This new era has been ushered in by improvements in disease understanding, a shifting focus beyond simply symptom control, new therapeutic options, and improved treatment algorithms, emphasis on preventing disease progression, and avoiding bowel damage and disability. While acceptance of a more early-effective approach has grown, realization of identified therapeutic goals remains a significant challenge. The disease course across patients with IBD is highly variable and clinicians need validated means to help predict individual outcomes and future risk so that treatment can be adequately personalized to achieve these goals. They must also be equipped to identify appropriate disease measures for gauging therapeutic success and select optimal treatment from a growing armamentarium. All the while recognizing nuance in guidelines, patient preferences, and a constantly evolving field.

MondayNightIBD, a serialized CME-certified program strives to address complex clinical questions and close practice gaps.

Program Chair

Aline Charabaty, MD, AGAF, FACG (moderator)
Assistant Clinical Director of the Division of Gastroenterology
Johns Hopkins School of Medicine
Clinical Director of IBD
Johns Hopkins - Sibley Memorial Hospital
Washington, DC

Schedule

Activity Date	Topic	Faculty	Disclosures	Supported by educationalal grants from...	Pre-test Link	Post-test Link	Links to Clinical Conversations		LOs
April 25, 2022	Comprehensive Management of Post-Op Crohn's Disease	Robert Battat, MD, CM Assistant Professor Weill Cornell Medicine Jill Roberts Center for IBD New York, NY	Consulting Fees: Prometheus Laboratories	AbbVie, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Takeda Pharmaceuticals U.S.A., Inc.	Certificate period expired		here		1, 2, 3
May 2, 2022	Management of Complications of Crohn's Disease: Strictures	Britt Christensen, BSc, MBBS (Hons),FRACP, MPH, PhD Head of Inflammatory Bowel Disease Unit Gastroenterology Department The Royal Melbourne Hospital Melbourne, AU	Consulting Fees: AbbVie, Celgene, Celltrion, Dr. Falk Pharma International, Fresenius Kabi, Janssen, Takeda Contracted Research: Arena Pharmaceuticals, Eli Lilly & Company, Janssen, Takeda	AbbVie, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Takeda Pharmaceuticals U.S.A., Inc.	Certificate period expired		Part 1: here	Part 2: here	1, 2, 3
May 9, 2022	Therapeutic Drug Monitoring	B. Evana Ghassemi, PharmD. APH, BCPS, BCACP IBD Clinical Pharmacist, Drug Use Management Kaiser Permanente Oakland, CA	Nothing to disclose	AbbVie, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Takeda Pharmaceuticals U.S.A., Inc.	Certificate period expired		here		2
May 16, 2022	Extra-intestinal Manifestations of IBD	Mehak Bassi, MD Chief Resident at Rutgers Biomedical and Health Sciences Department of Medicine, Rutgers Biomedical and Health Sciences Newark, NJ Joseph Sleiman, MD Gastroenterology Fellowship, PGY-4 Division of Gastroenterology, Hepatology and Nutrition UPMC Presbyterian Pittsburgh, PA	Nothing to disclose Nothing to disclose	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Takeda Pharmaceuticals U.S.A., Inc	Certificate period expired				2
June 6, 2022	De-escalation of Therapy	Shomron Ben-Horin, MD Professor Sackler School of Medicine Tel-Aviv Univesity Scientific Council Associate Professor, First Hospital Sun-Yitsan Univesity Crohn's and Colitis Association (ECCO) Chair, IBD Department Israeli Gastrointestinal Association Tel-Aviv, Israel	Consulting Fees: AbbVie, Bristol Myers-Squibb, Celltrion, Eli Lilly, Ferring, Galmed, Gilead, GlaxoSmithKline, Janssen, Medial Earlysign, NeoPharm, Novartis, Pfizer, Predicta Med, Roche, Takeda Contracted Research: Abbvie, Celltrion, Galmed, Janssen, Pfizer, Takeda Honoraria: AbbVie, Bristol Myers-Squibb, Celltrion, Eli Lilly, Falk, Ferring, Galmed, Gilead, GlaxoSmithKline, Janssen, Medial Earlysign, NeoPharm, Novartis, Perrigo, Pfizer, Predicta Med, Roche, Takeda Speakers' Bureau: AbbVie, Bristol Myers-Squibb, Celltrion, Eli Lilly, Falk, Ferring, Galmed, Gilead, GlaxoSmithKline, Janssen, Medial Earlysign, NeoPharm, Novartis, Perrigo, Pfizer, Predicta Med, Roche, Takeda Stock: Biotics, Evinature, Galmed, Predicta Med	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Takeda Pharmaceuticals U.S.A., Inc	Certificate period expired		Part 1: here	Part 2: here	2, 8
June 13, 2022	Non-inflammatory causes of GI symptoms in quiescent IBD	John Damianos, MD Resident Physician Yale-New Haven Hospital Department of Internal Medicine Yale University School of Medicine New Haven, CT Katie Dunleavy, MB. BCh. BAO Fellow Division of Gastroenterology & Hepatology Mayo Clinic Rochester, MN	Nothing to disclose Nothing to disclose	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, and Takeda Pharmaceuticals U.S.A., Inc	Certificate period expired		Part 1: here	Part 2: here	1, 2, 3, 4
June 20, 2022	LGBTQ considerations w/ IBD	Kira Newman, MD, PhD Gastroenterology and Hepatology Fellow Division of Gastroenterology & Hepatology University of Michigan Health Systems Ann Arbor, MI	Nothing to disclose	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, and Takeda Pharmaceuticals U.S.A., Inc	Certificate period expired		here		3, 4, 8
June 27, 2022	Management of COVID-19 in a IBD Patient on Biologic	Farah Monzur, MD Program Director, GI Fellowship Assistant Professor of Medicine Division of Gastroenterology and Hepatology Stony Brook Medicine Stony Brook, NY	Consulting Fees: Medtronic (Covidien) Contracted Research: Tigenix	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, and Takeda Pharmaceuticals U.S.A., Inc	Certificate period expired		here		2, 3, 6, 7, 8
July 11, 2022	Differential for dermatologic manifestations of IBD	Michael Kattah, MD, PhD Assistant Professor, Medicine Division of Gastroenterology University of California San Francisco San Francisco, CA Roberto Ricardo-Gonzalez, MD, PhD Assistant Professor, Dermatology School of Medicine University of California San Francisco San Francisco, CA	Contracted Research: Lilly Nothing to disclose	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, and Takeda Pharmaceuticals U.S.A., Inc	Certificate period expired		here		2
July 18, 2022	Dermatologic Manifestations of IBD #Back2Basics	Romy Chamoun, MD Internal Medicine Resident Lankenau Medical Center Wynnewood, Philadelphia Sanjeevani Tomar, MD Internal Medicine Resident Physician Department of Medicine Jacobs School of Medicine and Biomedical Sciences University at Buffalo (SUNY) Buffalo, NY Mehak Bassi, MD Chief Resident at Rutgers Biomedical and Health Sciences Department of Medicine, Rutgers Biomedical and Health Sciences Newark, NJ	Nothing to disclose Nothing to disclose Nothing to disclose	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, and Takeda Pharmaceuticals U.S.A., Inc	Certificate period expired				2
July 25, 2022	Setting up an IBD Practice	Tauseef Ali, MD, FACG Clinical Assistant Professor of Medicine Section of Digestive Disease and Nutrition University of Oklahoma Chief, Gastroenterology Medical Staff Section SSM Health St. Anthony Hospital Oklahoma City, OK	Consulting Fees: Abbvie, Janssen Contracted Research: Abbvie, Eli Lilly, Janssen Speakers Bureau: AbbVie, Bristol Myers Squibb, Janssen, Takeda	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, and Takeda Pharmaceuticals U.S.A., Inc	Certificate period expired				4,9
August 1, 2022	C. difficile Infection in Patients with IBD #Back2Basics	Haley Mertens, MD Internal Medicine Chief Resident in Quality and Safety Medical College of Wisconsin Clement J. Zablocki VA Medical Center Milwaukee, WI John S. Kelley, MD, MBA IM Resident Baylor Scott & White Health Temple, TX	Nothing to disclose Nothing to disclose	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, and Takeda Pharmaceuticals U.S.A., Inc	Certificate period expired				2,3,5,7
August 8, 2022	C. difficile Infection in Patients with IBD #MNIBDWebinar	Jessica Allegretti, M.D., M.P.H Associate Director, Crohn's and Colitis Center Division of Gastroenterology, Hepatology and Endoscopy Director, Fecal Microbiota Transplant Program Director of Clinical Research Brigham and Women's Hospital Assistant Professor of Medicine, Harvard Medical School Boston, MA	Consulting Fee: AbbVie, Artugen, BMS, Finch, Janssen, Iterative Scopes, Merck, Pfizer, Seres Contracted Research: Janssen, Pfizer, Merck Speakers Bureau: Bristol Myers Squibb	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, and Takeda Pharmaceuticals U.S.A., Inc	Certificate period expired				2,3,5,7
August 15, 2022	Symptoms of IBD: Beyond the Usual Suspects #Back2Basics	Ifrah Fatima, MBBS Resident Physician, Internal Medicine University of Missouri- Kansas City Kansas City, MO Sanjeevani Tomar, MD Internal Medicine Resident Physician Department of Medicine Jacobs School of Medicine and Biomedical Sciences University at Buffalo (SUNY) Buffalo, NY	Nothing to disclose Nothing to disclose	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, and Takeda Pharmaceuticals U.S.A., Inc	Certificate period expired				1,2
August 22, 2022	IBD Classification & Scoring Systems #Back2Basics	Romy Chamoun, MD Internal Medicine Resident Lankenau Medical Center Wynnewood, Philadelphia, PA Yara Sarkis, MD IM residency Indiana University Bloomington, IN	Nothing to disclose Nothing to disclose	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, and Takeda Pharmaceuticals U.S.A., Inc	Certificate period expired				1,2
August 29, 2022	Treatment Targets: Nuances and Patient Preferences #MNIBDWebinar	Sara Horst, MD, MPH, FACG Associate Professor Division of Gastroenterology, Hepatology, & Nutrition Vanderbilt University Medical Center Nashville, TN	Consulting Fees: AbbVie, Gilead, Janssen, Takeda	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, and Takeda Pharmaceuticals U.S.A., Inc	Certificate period expired				1,2,7
September 19, 2022	GETECCU X MNIBD #Back2Basics	Vicent Hernandez, MD, PhD Department of Gastroenterology Hospital Alvaro Cunqueiro Galicia Sur Health Research Institute Vigo, Spain	Consulting Fees: Takeda Speaker's Bureau: Ferring, Fresenius-Kabi, Janssen, MSD	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, and Takeda Pharmaceuticals U.S.A., Inc	Certificate period expired				2, 3, 5, 7
September 26, 2022	GETECCU X MNIBD Case Convo	Vicent Hernandez, MD, PhD Department of Gastroenterology Hospital Alvaro Cunqueiro Galicia Sur Health Research Institute Vigo, Spain	Consulting Fees: Takeda Speaker's Bureau: Ferring, Fresenius-Kabi, Janssen, MSD	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, and Takeda Pharmaceuticals U.S.A., Inc	Certificate period expired				2, 3, 5, 7
October 3, 2022	Thiopurines in IBD #Back2Basics	Joseph Sleiman, MD Gastroenterology Fellowship, PGY-4 Division of Gastroenterology, Hepatology and Nutrition UPMC Presbyterian Pittsburgh, PA	Nothing to disclose	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Takeda Pharmaceuticals U.S.A., Inc	Certificate period expired				2, 5
October 31, 2022	Debunking Myths in IBD #Back2Basics	Haley Mertens, MD Internal Medicine Chief Resident in Quality and Safety Medical College of Wisconsin Clement J. Zablocki VA Medical Center Milwaukee, WI Joseph Sleiman, MD Gastroenterology Fellowship, PGY-4 Division of Gastroenterology, Hepatology and Nutrition UPMC Presbyterian Pittsburgh, PA	Nothing to disclose Nothing to disclose	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Takeda Pharmaceuticals U.S.A., Inc	Certificate period expired				2, 6, 8
November 7, 2022	UC Refractory to TNFi - Considerations for Next Therapies	Aline Charabaty, MD, AGAF, FACG Assistant Clinical Director of the Division of Gastroenterology Johns Hopkins School of Medicine Clinical Director of IBD Johns Hopkins - Sibley Memorial Hospital Washington, DC	Consulting Fees: AbbVie, Bristol Myers Squibb, Janssen, Pfizer, Takeda	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Takeda Pharmaceuticals U.S.A., Inc	Certificate period expired				2, 6, 7
November 14, 2022	Medication Safety During Pregnancy	Joshua Steinberg, MD Director of IBD Gastroenterology of the Rockies Staff Gastroenterologist SCL Health Lutheran Medical Center, St. Joseph's Hospital Denver, CO	Consulting Fees: Bristol Myers Squibb, GistMD, Janssen, Pfizer Speaker's Bureau: AbbVie, Bristol Myers Squibb, Takeda	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Takeda Pharmaceuticals U.S.A., Inc	here	here			2, 6, 7
November 21, 2022	Perianal Fistula in Crohn’s Disease #Back2Basics	Mehak Bassi, MD Chief Resident at Rutgers Biomedical and Health Sciences Department of Medicine, Rutgers Biomedical and Health Sciences Newark, NJ	Nothing to disclose	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Takeda Pharmaceuticals U.S.A., Inc	here	here			2, 3, 5
November 28, 2022	Adalimumab Biosimilars Coming in 2023	Shubha Bhat, PharmD, MS, BCACP Clinical Assistant Professor of Medicine Cleveland Clinic Lerner College of Medicine Cleveland, OH	Consulting Fees: Bristol Myers Squibb, Boehringer Inhelheim, Pharmacosmos, Prometheus Laboratories Speaker's Bureau: Prometheus Laboratories	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Takeda Pharmaceuticals U.S.A., Inc	here	here			2, 5, 6, 7
December 12, 2022	IBD Barriers & Educational Needs	Aline Charabaty, MD, AGAF, FACG Assistant Clinical Director of the Division of Gastroenterology Johns Hopkins School of Medicine Clinical Director of IBD Johns Hopkins - Sibley Memorial Hospital Washington, DC	Consulting Fees: AbbVie, Bristol Myers Squibb, Janssen, Pfizer, Takeda	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Takeda Pharmaceuticals U.S.A., Inc	here	here			2, 4
December 19, 2022	Prepping for the Holiday Season	Dheera Grover, MBBS Resident UConn Health Center Farmington, CT Marcel Jose Yibirin, MD, MPH Resident Boston Medical Center Boston, MA	Nothing to disclose Nothing to disclose	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Takeda Pharmaceuticals U.S.A., Inc	here	here			8, 9
January 9, 2023	IBD & Obesity #Back2Basics	Mehak Bassi, MD Chief Resident at Rutgers Biomedical and Health Sciences Department of Medicine, Rutgers Biomedical and Health Sciences Newark, NJ Ifrah Fatima, MBBS Resident Physician, Internal Medicine University of Missouri- Kansas City Kansas City, MO Marcel Jose Yibirin, MD, MPH Resident Boston Medical Center Boston, MA	Nothing to disclose Nothing to disclose Nothing to disclose	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Takeda Pharmaceuticals U.S.A., Inc	here	here			2, 3, 7
January 16, 2023	IBD & Obesity	Poonam Beniwal-Patel, MD Division of Gastroenterology & Hepatology Medical College of Wisconsin Milwaukee, WI	Nothing to disclose	AbbVie, Ferring Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Takeda Pharmaceuticals U.S.A., Inc	here	here			2-4, 7-9
February 27, 2023	Lymphoma Risks in IBD #Back2Basics	Joseph Sleiman, MD Gastroenterology Fellowship, PGY-4 Division of Gastroenterology, Hepatology and Nutrition UPMC Presbyterian Pittsburgh, PA	Nothing to disclose	AbbVie, Ferring Pharmaceuticals, and Takeda Pharmaceuticals U.S.A., Inc	here	here			2,3,7,8
March 6, 2023	Lymphoma Risks in IBD Case Convo	Jeffrey M. Dueker, MD, MPH Assistant Professor of Medicine Associate Program Director Division of Gastroenterology, Hepatology and Nutrition University of Pittsburgh Medical Center	Nothing to disclose	AbbVie, Ferring Pharmaceuticals, and Takeda Pharmaceuticals U.S.A., Inc	here	here			2,3,7,8
March 20, 2023	GETECCU X MNIBD #Back2Basics	Vicent Hernandez, MD, PhD Department of Gastroenterology Hospital Alvaro Cunqueiro Galicia Sur Health Research Institute Vigo, Spain	Consulting Fees: Takeda Speaker's Bureau: Ferring, Fresenius-Kabi, Janssen, MSD	AbbVie, Ferring Pharmaceuticals, and Takeda Pharmaceuticals U.S.A., Inc	here	here			1, 2, 3, 5, 7, 8
March 27, 2023	GETECCU X MNIBD Case Convo	Vicent Hernandez, MD, PhD Department of Gastroenterology Hospital Alvaro Cunqueiro Galicia Sur Health Research Institute Vigo, Spain	Consulting Fees: Takeda Speaker's Bureau: Ferring, Fresenius-Kabi, Janssen, MSD	AbbVie, Ferring Pharmaceuticals, and Takeda Pharmaceuticals U.S.A., Inc	here	here			2, 3, 5, 7
April 17, 2023	IBD Mimickers	Yara Sarkis, MD IM residency Indiana University Bloomington, IN Mehak Bassi, MD Chief Resident at Rutgers Biomedical and Health Sciences Department of Medicine, Rutgers Biomedical and Health Sciences, Newark, NJ	Nothing to disclose Nothing to disclose	Abbvie, Takeda Pharmaceuticals U.S.A., Inc	here	here			2, 3, 7
April 24, 2023	Microscopic Colitis	Eugene Yen, MD Associate Professor of Medicine Gastroenterology & Hepatology Feinberg School of Medicine Northwestern University Chicago, IL	Consulting Fees: Boehringer Ingelheim, Ferring, Finch, Fresenius Kabi, Janssen Speakers Bureau: Abbvie	Abbvie, Takeda Pharmaceuticals U.S.A., Inc	here	here			2, 8
May 1, 2023	Small Bowel Adenocarcinoma	Daniel J. Stein MD Medical Director, IBD Program Froedtert and Medical College of Wisconsin Associate Professor of Medicine Milwaukee, WI	Consulting Fees: AbbVie, Allergan, Bristol Myers Squibb Contracted Research: Janssen, Pfizer Speakers Bureau: AbbVie, Bristol Myers Squibb, Lilly, Takeda	Abbvie, Takeda Pharmaceuticals U.S.A., Inc	here	here			2, 7, 8
May 15, 2023	IBD & Fertility	Zoë Gottlieb, MD Assistant Professor of Medicine Henry D. Janowitz Division of Gastroenterology Icahn School of Medicine at Mount Sinai, New York, New York	Contracted Research: Janssen, Pfizer	Abbvie, Takeda Pharmaceuticals U.S.A., Inc	here	here			2,3,4,6,7,8,9
May 22, 2023	Transition of care	Wade Billings, MD Gastroenterology Fellow Indiana University School of Medicine Indianapolis, IN	Nothing to disclose	Abbvie, Takeda Pharmaceuticals U.S.A., Inc					4,8,9

Target Audience

Gastroenterologists (GIs), GIs in training, surgeons, subspecialists such as dieticians and psychologists, nurse practitioners (NPs), physician assistants (PAs), nurses, and other healthcare team members involved in or interested in the care of patients with IBD.

Learning Objectives

After completing this activity series, the participant should be better able to:

DISTINGUISH objective measures of disease activity to prevent disease progression, bowel damage, and disability in patients with IBD
IDENTIFY guideline-directed strategies and best practices for the care of patients with IBD
TRANSLATE best practices for difficult-to-treat patients with IBD within clinical practice
LOCATE crowdsourcing initiatives designed to help optimize treatment of patients with difficult-to-treat IBD
RECOGNIZE safety and efficacy data from clinical trials of new and emerging agents to achieve an individualized, patient-centered approach to IBD management
ANALYZE potential approaches for positioning new and emerging therapies for UC
EVALUATE complex clinical situations in which patients with IBD may benefit from management strategies including novel therapeutics
EMPLOY a patient-centered approach in IBD shared-decision making
RECALL the importance of the interprofessional team in the provision of care for patients with IBD

Disclosures of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Aline Charabaty, MD, (chair)
Consulting: AbbVie, Bristol Myers Squibb, Janssen, Pfizer, Takeda
Lindsay Borvansky
Nothing to disclose
Ashley Cann
Nothing to disclose
Bonum CE staff and others involved with the planning, development, and review of the content for this activity have no relevant financial relationships to disclose.

Certification

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Bonum Continuing Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit & Fee Information

In order to receive credit for this activity, the participant must read the front matter, achieve a passing score of 100% on the post-survey, complete the evaluation and application for credit form.

Completion of the above referenced materials must be submitted to the program organizers within one year of the case conversation launch date. Requests for credit made more than 12 months following each activity posting date will not be eligible for a certificate. The organizers encourage learners, particularly those with regular participation in MondayNightIBD activities, to complete post-surveys, evaluation & credit claim forms on a weekly or monthly basis if at all possible.

There is no fee to participate in this program.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group, collaborators, and faculty on this program do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirements

All Bonum CE digital activities require the following hardware/software to view and participate:

Internet connection (via PC or Mac desktop or laptop computer, tablet, mobile device, etc.)
PowerPoint and/or a PDF viewer may be required on some activities

We recommend a minimum of:

128MB RAM
Processor speed of 500MHz or higher
800x600 color monitor
Video or graphics card
Sound card and speakers

To actively participate in Bonum’s social media (SoMe)-based CME programs, learners will need to have an established account in good standing on that hosting SoMe site. Learners will need to be logged-in to the SoMe hosting platform.

Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Estimated time to complete each activity: 60 minutes